# Thymosin Alpha 1 to Prevent COVID-19 Infection in Renal Dialysis Patients

> **NCT04428008** · PHASE2 · COMPLETED · sponsor: **William B. Ershler, MD** · enrollment: 189 (actual)

## Conditions studied

- COVID-19

## Interventions

- **DRUG:** Thymalfasin

## Key facts

- **NCT ID:** NCT04428008
- **Lead sponsor:** William B. Ershler, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-01-12
- **Primary completion:** 2023-01-19
- **Final completion:** 2023-01-19
- **Target enrollment:** 189 (ACTUAL)
- **Last updated:** 2026-04-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04428008

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04428008, "Thymosin Alpha 1 to Prevent COVID-19 Infection in Renal Dialysis Patients". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04428008. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*